Parallax Volatility Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-9,000
| Closed | -$495K | – | 1609 |
|
|
2025
Q2 | $495K | Sell |
9,000
-37,500
| -81% | -$2.21M | ﹤0.01% | 1191 |
|
|
2025
Q1 | $3.29M | Sell |
46,500
-33,600
| -42% | -$2.26M | 0.01% | 732 |
|
|
2024
Q4 | $5.26M | Buy |
80,100
+13,500
| +20% | +$904K | 0.01% | 802 |
|
|
2024
Q3 | $4.68M | Sell |
66,600
-104,200
| -61% | -$8.71M | 0.01% | 818 |
|
|
2024
Q2 | $14.1M | Buy |
170,800
+110,000
| +181% | +$9.16M | 0.03% | 379 |
|
|
2024
Q1 | $5.31M | Sell |
60,800
-6,600
| -10% | -$591K | 0.01% | 715 |
|
|
2023
Q4 | $6.5M | Buy |
67,400
+7,200
| +12% | +$637K | 0.01% | 745 |
|
|
2023
Q3 | $5.33M | Buy |
60,200
+35,700
| +146% | +$3.18M | 0.01% | 740 |
|
|
2023
Q2 | $2.12M | Sell |
24,500
-43,400
| -64% | -$4.08M | ﹤0.01% | 1115 |
|
|
2023
Q1 | $6.6M | Sell |
67,900
-34,000
| -33% | -$3.52M | 0.01% | 738 |
|
|
2022
Q4 | $10.5M | Buy |
101,900
+4,800
| +5% | +$451K | 0.02% | 752 |
|
|
2022
Q3 | $8.23M | Buy |
97,100
+97,000
| +97,000% | +$8.64M | 0.01% | 825 |
|
|
2022
Q2 | $8K | Sell |
100
-200
| -67% | -$15.9K | ﹤0.01% | 2690 |
|
|
2022
Q1 | $23K | Sell |
300
-31,400
| -99% | -$2.63M | ﹤0.01% | 2586 |
|
|
2021
Q4 | $2.8M | Buy |
+31,700
| New | +$2.62M | ﹤0.01% | 1476 |
|
|
2021
Q3 | – | Sell |
-56,200
| Closed | -$4.69M | – | 3014 |
|
|
2021
Q2 | $4.69M | Hold |
56,200
| – | – | ﹤0.01% | 1261 |
|
|
2021
Q1 | $4.24M | Buy |
56,200
+6,200
| +12% | +$506K | ﹤0.01% | 1375 |
|
|
2020
Q4 | $4.38M | Sell |
50,000
-24,000
| -32% | -$1.9M | ﹤0.01% | 1487 |
|
|
2020
Q3 | $5.63M | Sell |
74,000
-16,100
| -18% | -$1.63M | ﹤0.01% | 1253 |
|
|
2020
Q2 | $11.1M | Buy |
90,100
+48,400
| +116% | +$4.81M | 0.01% | 733 |
|
|
2020
Q1 | $3.52M | Buy |
+41,700
| New | +$3.59M | ﹤0.01% | 1005 |
|
|
2019
Q2 | – | Sell |
-13,500
| Closed | -$1.2M | – | 2584 |
|
|
2019
Q1 | $1.2M | Sell |
13,500
-15,700
| -54% | -$1.46M | ﹤0.01% | 1194 |
|
|
2018
Q4 | $2.49M | Hold |
29,200
| – | – | ﹤0.01% | 972 |
|
|
2018
Q3 | $2.83M | Hold |
29,200
| – | – | ﹤0.01% | 913 |
|
|
2018
Q2 | $2.75M | Buy |
+29,200
| New | +$2.56M | ﹤0.01% | 803 |
|
|
2016
Q1 | – | Sell |
-100,000
| Closed | -$10.5M | – | 2525 |
|
|
2015
Q4 | $10.5M | Buy |
100,000
+75,000
| +300% | +$7.83M | 0.02% | 447 |
|
|
2015
Q3 | $2.63M | Hold |
25,000
| – | – | 0.01% | 900 |
|
|
2015
Q2 | $3.42M | Buy |
+25,000
| New | +$3.1M | 0.01% | 859 |
|
Other funds holding BMRN
Parallax Volatility Advisers's BMRN Position: Q2 2025 in Review
Parallax Volatility Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 14,133 shares — an estimated $832K sold.
Parallax Volatility Advisers first reported a position in BMRN in Q1 2014 and held it in 22 quarters. The position peaked at $2.56M in Q2 2021. 582 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.
- Parallax Volatility Advisers reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Parallax Volatility Advisers sold 14,133 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $832K.
- Parallax Volatility Advisers first reported a position in BioMarin Pharmaceuticals in Q1 2014 and held it in 22 quarters.
- Parallax Volatility Advisers's BioMarin Pharmaceuticals position peaked at $2.56M in Q2 2021.
- 582 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.
Based on Parallax Volatility Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.